Comparative Pharmacology
Head-to-head clinical analysis: QUASENSE versus TRI PREVIFEM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QUASENSE versus TRI PREVIFEM.
QUASENSE vs TRI-PREVIFEM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Quetiapine antagonist at dopamine D2 and serotonin 5-HT2A receptors; also affects histamine H1 and adrenergic α1 and α2 receptors.
Combination oral contraceptive: ethinyl estradiol and norgestimate exert contraceptive effects primarily by suppression of gonadotropin secretion (FSH and LH), thereby inhibiting ovulation. Additionally, progestin induces changes in cervical mucus and endometrial receptivity.
100 mg orally every 12 hours.
One tablet (norgestimate 0.180 mg/ethinyl estradiol 0.025 mg) orally once daily for 21 days, followed by 7 days of placebo; repeat cycle.
None Documented
None Documented
Terminal elimination half-life is 8–12 hours in healthy adults; prolonged to 20–30 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Ethinyl estradiol: terminal half-life 13-27 hours; norgestimate: terminal half-life of norelgestromin (active metabolite) 12-30 hours; clinical context: once-daily dosing provides steady-state concentrations within 7-10 days.
Primarily renal excretion (approximately 70% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal elimination accounts for about 20% (including metabolites); 10% undergoes metabolic clearance.
Ethinyl estradiol: 40% renal, 60% fecal; norgestimate and its metabolites: 80% renal, 20% fecal.
Category C
Category C
Oral Contraceptive
Oral Contraceptive